Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Extended release injectable suspension"'
Autor:
Reimbursement Team
Publikováno v:
Canadian Journal of Health Technologies. 1
CADTH recommends that Perseris should be reimbursed by public drug plans for the treatment of schizophrenia in adults if certain conditions are met. Perseris should be covered by public drug plans in a similar manner to other long-acting injectable a
Autor:
John J. Mariani, Martina Pavlicova, C. Jean Choi, Adam Bisaga, Kaitlyn Mishlen, Maria A. Sullivan, Kenneth M. Carpenter, Edward V. Nunes, Frances R. Levin
Publikováno v:
American Journal of Psychiatry. 176:129-137
The oral formulation of the opioid antagonist naltrexone has shown limited effectiveness for treatment of opioid use disorder due to poor adherence. Long-acting injection naltrexone (XR-naltrexone), administered monthly, circumvents the need for dail
Publikováno v:
Value in Health. 21:S197-S198
Autor:
John C. Richmond, Scott Kelley, J.R. Johnson, Deryk G. Jones, Joelle Lufkin, Andreas H. Gomoll, Andrew I. Spitzer, Virginia B. Kraus
Publikováno v:
Osteoarthritis and Cartilage. 26:S251-S252
Autor:
R. Sala, R. Manning, S.J. Russell, Scott Kelley, Joelle Lufkin, J.R. Johnson, G. Habib, Y. Davis, P.G. Conaghan, Alan Kivitz, Q. Vo
Publikováno v:
Osteoarthritis and Cartilage. 26:S230
Publikováno v:
European Psychiatry. 33:S305-S305
IntroductionStudies describe patients with dual pathology as subjects with worse clinical evolution and worse therapeutic response. These subjects have high percentages of worse therapeutic compliance and low adherence to psychopharmacological treatm